The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

[1]  O. Faber,et al.  Variation in125i-insulin absorption and blood glucose concentration , 1979, Diabetologia.

[2]  U. Ribel,et al.  Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs , 1996, Diabetologia.

[3]  S. Emdin,et al.  Role of zinc in insulin biosynthesis , 1980, Diabetologia.

[4]  S. Skeie,et al.  Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. , 2003, Diabetes care.

[5]  R. Bergman,et al.  Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake. , 2002, Diabetes.

[6]  R. Bergman,et al.  Mode of transcapillary transport of insulin and insulin analog NN304 in dog hindlimb: evidence for passive diffusion. , 2002, Diabetes.

[7]  B. Zinman,et al.  Insulins today and beyond , 2001, The Lancet.

[8]  A M Gualandi-Signorini,et al.  Insulin formulations--a review. , 2001, European review for medical and pharmacological sciences.

[9]  K. Hermansen,et al.  Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. , 2001, Diabetes care.

[10]  G. Bolli.  Physiological insulin replacement in type 1 diabetes mellitus. , 2001, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[11]  P. Brunetti,et al.  Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. , 2000, Diabetes.

[12]  N. Kaarsholm,et al.  Structural effects of protein lipidation as revealed by LysB29-myristoyl, des(B30) insulin. , 2000, Biochemistry.

[13]  D R Owens,et al.  Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. , 2000, Diabetes care.

[14]  L Heinemann,et al.  Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. , 2000, Diabetes care.

[15]  M. Ellmerer,et al.  Measurement of interstitial albumin in human skeletal muscle and adipose tissue by open-flow microperfusion. , 2000, American journal of physiology. Endocrinology and metabolism.

[16]  M. Ellmerer,et al.  Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. , 2000, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[17]  R. Bergman,et al.  Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin , 1999, Diabetologia.

[18]  G. Bolli,et al.  Insulin analogues and their potential in the management of diabetes mellitus , 1999, Diabetologia.

[19]  L. Heinemann,et al.  Time‐action profile of the soluble, fatty acid acylated, long‐acting insulin analogue NN304 , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[20]  A. Vølund,et al.  Insulin analogs with improved pharmacokinetic profiles. , 1999, Advanced drug delivery reviews.

[21]  N. Kaarsholm,et al.  The relationship between insulin bioactivity and structure in the NH2-terminal A-chain helix. , 1998, Journal of molecular biology.

[22]  S. Havelund,et al.  Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. , 1997, Journal of pharmaceutical sciences.

[23]  J. Whittingham,et al.  Crystal structure of a prolonged-acting insulin with albumin-binding properties. , 1997, Biochemistry.

[24]  S. Havelund,et al.  The acylated insulin , 1996 .

[25]  U. Ribel,et al.  Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. , 1995, The Biochemical journal.

[26]  U. Ribel,et al.  Action Profile of Cobalt(III)-Insulin: A Novel Principle of Protraction of Potential Use for Basal Insulin Delivery , 1995, Diabetes.

[27]  S. Gammeltoft,et al.  Receptor Binding and Tyrosine Kinase Activation by Insulin Analogues With Extreme Affinities Studied in Human Hepatoma HepG2 Cells , 1991, Diabetes.

[28]  D R Owens,et al.  Subcutaneous Insulin Absorption Explained by Insulin's Physicochemical Properties: Evidence From Absorption Studies of Soluble Human Insulin and Insulin Analogues in Humans , 1991, Diabetes Care.

[29]  P Hildebrandt,et al.  Subcutaneous absorption of insulin in insulin-dependent diabetic patients. Influence of species, physico-chemical properties of insulin and physiological factors. , 1991, Danish medical bulletin.

[30]  D R Owens,et al.  Monomeric Insulins and Their Experimental and Clinical Implications , 1990, Diabetes Care.

[31]  P. Hougaard,et al.  Soluble, prolonged-acting insulin derivatives. III. Degree of protraction, crystallizability and chemical stability of insulins substituted in positions A21, B13, B23, B27 and B30. , 1988, Protein engineering.

[32]  J. Brange,et al.  Monomeric insulins obtained by protein engineering and their medical implications , 1988, Nature.

[33]  P. Hougaard,et al.  Soluble, prolonged-acting insulin derivatives. II. Degree of protraction and crystallizability of insulins substituted in positions A17, B8, B13, B27 and B30. , 1987, Protein engineering.

[34]  P. Sejrsen,et al.  Diffusion and polymerization determines the insulin absorption from subcutaneous tissue in diabetic patients. , 1985, Scandinavian journal of clinical and laboratory investigation.